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Summary
Background The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, 
especially during public health emergencies. Development assistance is an important source of health financing in 
many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We 
aimed to put development assistance for health for COVID-19 in the context of broader trends in global health 
financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020.
Methods We estimated domestic health spending and development assistance for health to generate total health-sector 
spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure 
Database to produce estimates of domestic health spending. To generate estimates for development assistance for 
health, we relied on project-level disbursement data from the major international development agencies’ online 
databases and annual financial statements and reports for information on income sources. To adjust our estimates 
for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements 
from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), 
including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency 
Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ 
per capita, purchasing-power parity-adjusted US$ per capita, and as a proportion of gross domestic product. We used 
various models to generate future health spending to 2050.
Findings In 2019, health spending globally reached $8·8 trillion (95% uncertainty interval [UI] 8·7–8·8) or 
$1132 (1119–1143) per person. Spending on health varied within and across income groups and geographical regions. 
Of this total, $40·4 billion (0·5%, 95% UI 0·5–0·5) was development assistance for health provided to low-income 
and middle-income countries, which made up 24·6% (UI 24·0–25·1) of total spending in low-income countries. 
We estimate that $54·8 billion in development assistance for health was disbursed in 2020. Of this, $13·7 billion 
was targeted toward the COVID-19 health response. $12·3 billion was newly committed and $1·4 billion was 
repurposed from existing health projects. $3·1 billion (22·4%) of the funds focused on country-level coordination 
and $2·4 billion (17·9%) was for supply chain and logistics. Only $714·4 million (7·7%) of COVID-19 development 
assistance for health went to Latin America, despite this region reporting 34·3% of total recorded COVID-19 deaths 
in low-income or middle-income countries in 2020. Spending on health is expected to rise to $1519 (1448–1591) 
per person in 2050, although spending across countries is expected to remain varied.
Interpretation Global health spending is expected to continue to grow, but remain unequally distributed between 
countries. We estimate that development organisations substantially increased the amount of development assistance 
for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for 
the most vulnerable, and to help curtail the pandemic for all.
Funding Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
How much countries spend on health has long been of 
interest for relevance to a range of social and economic 
objectives, including the goal of providing essential 
health services and universal health coverage.1–6 The 
COVID-19 pandemic has renewed interest in the past, 
present, and future of global health financing, in part 
because responding to the COVID-19 pandemic has been 
and continues to be tremendously costly. Governments 
around the world implemented restrictions on travel 
and mass gatherings; required masks and quarantines; 
and rolled out and ramped up access to COVID-19 
testing, contact tracing, and, when possible, COVID-19 
treatment.7,8 Governments have fought to secure access 
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to the first round of approved COVID-19 vaccines, 
with vaccination campaigns beginning in more than 
30 countries in 2020, including China, Israel, Russia, 
Mexico, the USA, and the UK.9–11
Funding the pandemic response has been complicated 
by global economic recession, which has not spared low-
income and middle-income countries.12 It was estimated 
that the global economy shrank by 3·3% in 2020, and the 
economies of low-income and middle-income countries 
(excluding China) shrank by 4·3%.13 Uncertainty is 
expected to linger as third and fourth waves sweep the 
globe and new COVID-19 variants spread with increasing 
speed.14,15 Unemployment increased globally, and extreme 
poverty is estimated to have increased by between 
88 and 115 million in 2020.16 Moreover, the economic 
consequences of the health crisis are leading to 
long-standing reductions in economic development in 
some countries, and further indirect adverse effects on 
health.4,17–21
The response to the dual health and economic crises 
caused by COVID-19 generated substantial costs across 
countries. High-income countries and many middle-
income countries have been able to finance their 
government programmes with financial reserves, 
reallocation of government resources, and by 
borrowing. The International Monetary Fund (IMF) 
estimates that globally, government debt increased by 
$20 trillion between Sept 1, 2019, and Sept 1, 2020.22 
Although some low-income countries have also 
borrowed resources (obtaining loans at market rates) to 
fund their responses to the 2020 crises, development 
assistance plays a unique role in funding health 
systems during emergencies in many countries and 
can be a catalyst for rapidly scaling up novel health 
services.23
We estimated development assistance for health for 
COVID-19 in 2020, and assessed how that assistance 
compared with broader trends in health financing. 
We first present retrospective estimates of domestic 
spending on health and development assistance for 
health to provide context on the broader health financing 
landscape. Then we focus on development assistance for 
health and how it was used to target COVID-19 in 2020, 
and ramifications for development assistance for health 
funding in other essential health areas. We disaggregate 
estimates for development assistance for health for 
COVID in 2020 by funding sources, disbursing agencies, 
recipients, and programme areas to enable comparison 
with other key focus areas such as HIV/AIDS, health 
system strengthening, and pandemic preparedness. 
Research in context
Evidence before this study
The Global Burden of Disease Health Financing Collaborator 
Network and WHO have each published annual estimates of 
global health spending, with the former also publishing estimates 
of future health spending. So far, few research efforts have 
provided estimates of health spending associated with the 
COVID-19 pandemic, and these vary in their scope and 
completeness. The Economist Intelligence Unit’s COVID-19 
Health Funding Tracker provides visualisations of pledged and 
disbursed funding for pandemic response, although it does not 
include international commitments to individual countries or 
pledges less than US$2 million. The Kaiser Family Foundation 
Donor Funding for the Global Novel Coronavirus Response tracker 
is a tabulated database of funding pledged for the global response 
to COVID-19. This tracker has not been updated since April, 2020, 
and does not include resources for research and development or 
in-kind support. The Centre for Disaster Protection’s database 
tracks funding from multilateral agencies and regional 
development banks for global humanitarian and development 
needs, but does not capture bilateral or private contributions. 
Devex’s interactive website tracks funding committed toward 
addressing the health, social, economic, and environmental 
effects of the pandemic, but does not provide information on the 
disbursements of these funds. The COVID-19 Research Project 
tracker from the UK Collaborative on Development Research and 
the Global Research Collaboration for Infectious Disease 
Preparedness collates data on all research and development 
project commitments and maps these to WHO research priorities. 
Although these existing studies track various aspects of the 
funding targeted toward the pandemic response, none reports 
comprehensive tracking for the health sector.
Added value of this study
We track spending on health globally, providing estimates from 
1990 to 2050. We focus mainly on novel estimates of 
development assistance for health for COVID-19 in 2020 and 
the ramifications that follow for funding other essential health 
areas. These estimates add value to trackers by focusing on 
2020 disbursements, being as comprehensive as possible, and 
placing development assistance for health for COVID-19 in the 
context of past spending and projected future health spending.
Implications of all the available evidence
Since 1995, global health spending has increased constantly, but 
inequalities in spending remain. Our estimates suggest that 
although contributions have been forthcoming, there remains a 
gap in funding needed to fully address the effects of the 
pandemic in most low-income and middle-income countries, 
especially as vaccine roll-outs are initiated globally. Continued 
efforts are needed to raise the required resources to provide 
health care for the pandemic—prevention and treatment—for the 
most vulnerable. Beyond COVID-19, projected disparities in 
future health spending across income groups suggest an ongoing 
benefit of leveraging development assistance resources in 
promoting an equitable response to any future health 
emergencies.
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Finally, we generate estimates of future health spending 
to enable an assessment of the implications for future 
health financing.24,25 Comprehensive health spending 
estimates are important for examining potential gaps in 
resource needs versus available funding.
Methods
Overview
Health spending can be disaggregated into four key 
financing sources: government, out-of-pocket, and 
prepaid private health spending, which collectively 
make up domestic health spending; and development 
assistance for health, which includes international 
disbursements for health to low-income and middle-
income countries. Government health spending 
includes social health insurance and government public 
health programmes. Out-of-pocket health spending 
includes health-care spending by a patient or their 
household but excludes insurance premiums. Prepaid 
private health spending includes private insurance 
spending and spending by non-governmental agencies 
on health.
To estimate total health spending for 204 countries 
and territories, we estimated each of the four financing 
sources separately for the years that underlying data 
were available, and used past trends and relationships 
to forecast each financing source from the point where 
retrospective estimates end to the end of 2050. The 
primary data source for domestic spending financing 
streams was the WHO Global Health Expenditure 
Database (GHED), and retrospective estimates were 
made from 1995 to 2018. Development assistance for 
health was estimated by use of a diverse set of project 
and agency expenditure and revenue statements, and 
estimates extend from 1990 to 2020, with additional 
project-level databases used to generate special 
estimates of development assistance for health for 
COVID-19 in 2020 (appendix pp 26, 91). Forecasts for 
each financing source begin in 2019 or 2021. All 
estimates are inflation-adjusted and are mostly reported 
in 2020 US$, although some were adjusted for national 
prices and are thus reported in purchasing-power parity-
adjusted US$ or relative to gross domestic product 
(GDP).
Estimating domestic health spending, 1995–2018
For government, out-of-pocket, and prepaid private 
health spending, we downloaded data from the GHED 
for all available countries in current national currency 
units.26 We adjusted these estimates for inflation, 
converted to 2020 US$, modelled estimates to ensure 
consistency over time and comprehensiveness across 
countries and territories, and estimated uncertainty 
(appendix p 21). We also converted these estimates into 
2020 purchasing-power parity-adjusted US$. We used 
deflator series and exchange rate data based on data from 
the IMF World Economic Outlook.14
For each of the three domestic financing sources, we 
used the metadata provided by WHO to qualitatively 
assess the reliability of data extracted from the GHED. 
We assigned a weight to each downloaded datapoint 
according to the documented source information 
included in the metadata, completeness of metadata, and 
documented methods of estimation (appendix p 13). We 
then used a spatiotemporal Gaussian process model to 
generate a complete time series of data from 1995 until 
2018 for each country, and calculated 95% uncertainty 
intervals (UIs).27,28
Estimating development assistance for health, 
1990–2020
Development assistance for health refers to the financial 
and non-financial resources that are disbursed through 
international development agencies to maintain or 
improve health in low-income and middle-income 
countries. We tracked these disbursements from their 
originating sources through their disbursing agencies to 
the health focus areas that these resources were designed 
to target in recipient countries. Originating sources were 
typically the national treasuries of donor governments 
or private philanthropies from which development 
assistance funds are transferred. The funds from 
originating sources are channelled through international 
development agencies, which are here referred to as the 
disbursing agency, before being disbursed to the 
recipient country. We relied on project-level disbursement 
data from major international development agencies’ 
online databases, including the Organisation for 
Economic Cooperation and Development’s Creditor 
Reporting System (OECD CRS), the Global Fund to Fight 
AIDS, Tuberculosis and Malaria (the Global Fund), and 
annual financial state ments and reports for information 
on income sources. Data were not yet available for some 
more recent years, and we relied on budget data to 
generate these estimates. Detailed explanation of how 
the disbursements were estimated for each disbursing 
agency is provided in the appendix (pp 47–80) and 
published elsewhere.5,29–36 We disaggregated the estimates 
into ten health focus areas and 53 programme areas. 
This disaggregation captures the main programmatic 
areas to which development assistance for health 
contributions have historically been provided, and 
facilitates comparison with 2020 contributions and the 
international funding for the ongoing pandemic. We 
defined relevant health focus areas and programme areas 
for projects on the basis of a keyword search of the 
project descriptions downloaded from international 
agencies’ online project databases. The specific keywords 
we used and their assigned health focus or programme 
area are detailed in the appendix (pp 35–46).
We leveraged information from available financial 
documents on revenue to remove double counting 
across disbursing agencies, so that each flow of 
funding is counted only once even if it was moved 
For more on the WHO Global 
Health Expenditure Database 
see https://apps.who.int/nha/
database
See Online for appendix
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Health spending per 
person, 2019 (US$)
Projected health 
spending per person, 
2050 (2020 US$)
Health spending per 
person, 2019 ($PPP)
Projected health 
spending per person, 
2050 ($PPP)
Total health 
spending per GDP, 
2019
Total health 









Total 1132 (1119 to 1143) 1519 (1448 to 1591) 1485 (1470 to 1501) 2053 (1973 to 2135) 10·0% (9·8 to 10·1) 12·9% (11·5 to 14·2) 0·7
World Bank income groups
High income 5702 (5638 to 5769) 8539 (8074 to 9032) 6288 (6226 to 6356) 9322 (8871 to 9812) 12·6% (12·5 to 12·8) 17·6% (15·5 to 19·9) 0·0
Upper-middle 
income
500 (484 to 517) 1001 (922 to 1083) 984 (959 to 1011) 1915 (1783 to 2051) 5·7% (5·5 to 5·9) 8·3% (6·4 to 10·3) 0·0
Lower-middle 
income
90 (86 to 95) 150 (141 to 159) 281 (267 to 297) 461 (433 to 493) 4·1% (3·9 to 4·3) 4·6% (3·8 to 5·4) 0·1





571 (560 to 580) 656 (628 to 684) 1426 (1398 to 1453) 1635 (1564 to 1708) 6·0% (5·9 to 6·1) 7·0% (6·0 to 7·9) 0·2
High income 6282 (6211 to 6356) 9302 (8791 to 9852) 6773 (6701 to 6848) 9949 (9436 to 10 500) 13·1% (12·9 to 13·3) 18·1% (15·8 to 20·5) 0·0
Latin America 
and Caribbean
514 (497 to 530) 762 (710 to 824) 1163 (1125 to 1200) 1734 (1615 to 1873) 7·4% (7·2 to 7·6) 10·3% (8·7 to 12·0) 0·1
North Africa and 
Middle East
378 (370 to 386) 469 (444 to 498) 945 (926 to 967) 1225 (1154 to 1296) 5·8% (5·6 to 6·0) 8·6% (7·5 to 9·7) 0·0
South Asia 69 (62 to 77) 134 (119 to 150) 229 (207 to 255) 447 (397 to 502) 3·4% (3·1 to 3·8) 4·1% (2·9 to 5·6) 0·0
Southeast Asia, 
east Asia, and 
Oceania
439 (419 to 459) 1025 (915 to 1138) 766 (735 to 800) 1784 (1606 to 1966) 5·1% (4·8 to 5·3) 7·7% (5·6 to 10·3) 0·0
Sub-Saharan 
Africa
76 (74 to 79) 99 (94 to 106) 193 (187 to 199) 253 (240 to 268) 5·0% (4·8 to 5·2) 5·0% (4·4 to 5·7) 0·1
Central Europe, eastern Europe, and central Asia
Central Asia
Armenia 436 (409 to 462) 531 (495 to 568) 1387 (1301 to 1472) 1689 (1576 to 1807) 9·6% (8·6 to 10·6) 10·0% (6·7 to 13·9) 3·3
Azerbaijan 157 (140 to 174) 185 (161 to 211) 550 (492 to 612) 648 (567 to 741) 3·6% (3·2 to 4·0) 4·1% (2·8 to 6·0) 0·0
Georgia 330 (311 to 350) 516 (456 to 585) 1133 (1067 to 1201) 1773 (1568 to 2009) 7·4% (6·8 to 8·1) 10·5% (7·4 to 14·4) 0·0
Kazakhstan 282 (258 to 308) 403 (331 to 484) 855 (782 to 934) 1219 (1002 to 1465) 3·1% (2·8 to 3·4) 3·8% (2·6 to 5·4) 0·0
Kyrgyzstan 83 (79 to 88) 108 (98 to 121) 350 (333 to 369) 455 (412 to 510) 6·3% (6·0 to 6·7) 7·7% (5·7 to 10·2) 0·0
Mongolia 203 (187 to 222) 293 (254 to 345) 623 (575 to 683) 900 (781 to 1059) 4·8% (4·4 to 5·3) 5·9% (4·0 to 8·3) 9·4
Tajikistan 59 (56 to 61) 68 (62 to 77) 251 (240 to 262) 292 (264 to 329) 7·0% (6·4 to 7·6) 7·7% (5·4 to 10·8) 0·0
Turkmenistan 603 (559 to 648) 745 (680 to 814) 1247 (1157 to 1340) 1543 (1406 to 1685) 7·7% (7·1 to 8·4) 8·6% (6·0 to 12·0) 0·0
Uzbekistan 93 (85 to 102) 128 (112 to 145) 391 (356 to 427) 537 (469 to 606) 5·3% (4·8 to 5·8) 5·9% (4·1 to 8·4) 0·7
Central Europe
Albania 293 (270 to 317) 355 (319 to 396) 816 (753 to 884) 990 (888 to 1103) 5·5% (5·1 to 6·0) 6·0% (4·1 to 8·3) 0·0
Bosnia and 
Herzegovina
548 (517 to 582) 951 (872 to 1038) 1416 (1336 to 1503) 2457 (2253 to 2682) 9·0% (8·4 to 9·5) 12·2% (8·3 to 17·4) 0·0
Bulgaria 785 (745 to 826) 991 (847 to 1162) 1896 (1799 to 1997) 2396 (2047 to 2808) 7·7% (7·3 to 8·2) 8·9% (6·0 to 12·7) 0·0
Croatia 1024 (964 to 1082) 1299 (1040 to 1619) 2020 (1901 to 2134) 2563 (2052 to 3193) 6·7% (6·3 to 7·1) 8·4% (5·5 to 12·3) 0·0
Czech Republic 1851 (1789 to 1911) 2547 (2244 to 2869) 3296 (3186 to 3402) 4536 (3996 to 5109) 7·6% (7·1 to 8·3) 9·9% (6·8 to 13·6) 0·0
Hungary 1100 (1068 to 1133) 1296 (1197 to 1405) 2321 (2253 to 2390) 2734 (2526 to 2964) 6·7% (6·5 to 6·9) 7·2% (5·3 to 9·5) 0·0
Montenegro 732 (689 to 780) 814 (745 to 892) 1840 (1733 to 1960) 2047 (1873 to 2242) 8·1% (7·7 to 8·7) 9·0% (6·4 to 12·0) 0·0
North 
Macedonia
412 (396 to 429) 412 (378 to 449) 1137 (1092 to 1183) 1136 (1042 to 1239) 6·5% (6·0 to 7·0) 6·7% (5·1 to 8·7) 0·0
Poland 1023 (999 to 1048) 1461 (1338 to 1599) 2256 (2202 to 2310) 3221 (2949 to 3525) 6·4% (6·3 to 6·6) 8·7% (6·0 to 12·3) 0·0
Romania 773 (733 to 815) 1038 (861 to 1228) 1819 (1723 to 1917) 2440 (2025 to 2888) 5·8% (5·4 to 6·1) 6·7% (4·4 to 9·6) 0·0
Serbia 518 (505 to 533) 637 (598 to 677) 1302 (1268 to 1339) 1600 (1504 to 1700) 6·8% (6·6 to 7·0) 7·4% (5·4 to 9·7) 0·0
Slovakia 1375 (1317 to 1435) 1813 (1637 to 2046) 2373 (2272 to 2475) 3128 (2824 to 3530) 6·9% (6·6 to 7·2) 8·6% (5·9 to 11·6) 0·0
Slovenia 2248 (2186 to 2314) 2691 (2511 to 2883) 3456 (3360 to 3558) 4137 (3860 to 4432) 8·4% (8·1 to 8·6) 10·5% (7·4 to 14·5) 0·0
(Table 1 continues on next page)
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(Continued from previous page)
Eastern Europe
Belarus 361 (334 to 387) 459 (364 to 576) 1163 (1075 to 1248) 1480 (1174 to 1858) 5·7% (5·3 to 6·1) 6·6% (4·3 to 10·0) 0·0
Estonia 1628 (1586 to 1669) 2211 (1973 to 2456) 2623 (2555 to 2689) 3561 (3179 to 3956) 6·8% (6·6 to 7·0) 8·2% (5·7 to 11·4) 0·0
Latvia 1132 (1094 to 1170) 1384 (1259 to 1517) 2008 (1941 to 2075) 2456 (2233 to 2693) 6·2% (6·0 to 6·4) 7·1% (4·9 to 9·7) 0·0
Lithuania 1321 (1277 to 1364) 1649 (1519 to 1786) 2562 (2477 to 2646) 3198 (2947 to 3465) 6·6% (6·3 to 6·9) 7·3% (4·9 to 10·3) 0·0
Moldova 215 (198 to 232) 252 (225 to 285) 667 (6168 to 720) 783 (698 to 884) 5·8% (4·3 to 8·3) 7·1% (4·4 to 11·5) 0·0
Russia 563 (537 to 586) 611 (554 to 676) 1546 (1475 to 1610) 1679 (1522 to 1858) 5·4% (5·1 to 5·6) 6·2% (4·4 to 8·5) 0·0
Ukraine 258 (242 to 274) 259 (233 to 288) 957 (899 to 1015) 962 (865 to 1067) 7·4% (6·7 to 8·1) 8·4% (6·1 to 11·2) 0·0
High income
Australasia
Australia 5507 (5409 to 5608) 7818 (7303 to 8402) 5398 (5302 to 5498) 7663 (7159 to 8236) 10·3% (9·8 to 11·1) 13·6% (9·4 to 18·6) 0·0
New Zealand 4175 (4081 to 4269) 6012 (5553 to 6508) 4434 (4334 to 4534) 6386 (5898 to 6912) 9·9% (9·4 to 10·2) 13·2% (9·4 to 17·6) 0·0
High-income Asia Pacific
Brunei 544 (501 to 592) 490 (374 to 620) 1454 (1339 to 1583) 1310 (1001 to 1659) 2·3% (2·1 to 2·5) 2·5% (1·6 to 3·6) 0·0
Japan 4489 (4372 to 4622) 6150 (5583 to 6734) 4787 (4662 to 4929) 6558 (5953 to 7180) 10·9% (10·6 to 11·3) 14·4% (10·0 to 20·0) 0·0
Singapore 2843 (2719 to 2966) 5002 (4033 to 6083) 4645 (4443 to 4847) 8173 (6590 to 9940) 4·5% (4·3 to 4·8) 7·2% (4·6 to 10·6) 0·0
South Korea 2442 (2395 to 2487) 4957 (4470 to 5478) 3529 (3461 to 3594) 7165 (6461 to 7917) 7·8% (7·6 to 7·9) 14·1% (9·7 to 20·2) 0·0
High-income North America
Canada 5163 (5104 to 5218) 7077 (6531 to 7661) 5837 (5770 to 5899) 8000 (7383 to 8661) 11·2% (11·0 to 11·4) 15·1% (10·8 to 20·4) 0·0
Greenland 6579 (5966 to 7194) 7651 (6719 to 8606) 5381 (4879 to 5884) 6258 (5595 to 7038) 11·5% (10·1 to 13·0) 12·9% (8·8 to 18·2) 0·0
USA 11 345 (11 114 to 11 578) 17 300 (15 680 to 18 976) 11 345 (11 114 to 11 578) 17 300 (15 680 to 18 976) 17·2% (16·8 to 17·5) 24·8% (19·0 to 32·5) 0·0
Southern Latin America
Argentina 946 (905 to 988) 1239 (1086 to 1428) 2285 (2186 to 2387) 2993 (2624 to 3449) 9·7% (9·3 to 10·2) 13·0% (8·8 to 18·1) 0·0
Chile 1329 (1304 to 1353) 2025 (1885 to 2184) 2472 (2426 to 2516) 3765 (3505 to 4062) 9·7% (9·5 to 9·9) 14·0% (10·1 to 19·5) 0·0
Uruguay 1549 (1516 to 1585) 2268 (2009 to 2572) 2156 (2110 to 2205) 3157 (2796 to 3580) 9·5% (9·2 to 9·8) 11·9% (8·2 to 16·8) 0·0
Western Europe
Andorra 2948 (2827 to 3079) 2957 (2538 to 3587) 3141 (3012 to 3280) 3150 (2704 to 3822) 6·7% (5·9 to 7·8) 9·7% (6·6 to 13·9) 0·0
Austria 5383 (5302 to 5463) 6766 (6253 to 7294) 6132 (6039 to 6222) 7707 (7123 to 8308) 10·3% (10·1 to 10·5) 12·8% (8·8 to 17·3) 0·0
Belgium 4983 (4887 to 5083) 6490 (6019 to 6960) 5698 (5588 to 5813) 7421 (6882 to 7958) 10·4% (10·2 to 10·7) 12·7% (9·5 to 16·6) 0·0
Cyprus 1262 (1212 to 1313) 1582 (1443 to 1743) 1881 (1806 to 1957) 2358 (2150 to 2598) 5·0% (4·0 to 6·6) 6·2% (4·3 to 9·3) 0·0
Denmark 6182 (6035 to 6340) 8095 (7433 to 8849) 6112 (5967 to 6269) 8004 (7350 to 8750) 10·0% (9·7 to 10·3) 12·2% (9·2 to 15·8) 0·0
Finland 4595 (4504 to 4690) 5642 (5261 to 6023) 4680 (4587 to 4776) 5745 (5358 to 6134) 9·1% (8·9 to 9·3) 9·9% (7·3 to 13·1) 0·0
France 4844 (4792 to 4891) 6245 (5714 to 6811) 5605 (55475 to 5659) 7226 (6612 to 7881) 11·4% (11·0 to 11·7) 14·1% (10·8 to 18·0) 0·0
Germany 5498 (5428 to 5570) 7518 (6986 to 7987) 6482 (6399 to 6567) 8863 (8236 to 9416) 11·4% (11·2 to 11·5) 14·6% (10·4 to 19·5) 0·0
Greece 1595 (1515 to 1677) 1620 (1470 to 1785) 2551 (2422 to 2682) 2591 (2351 to 2854) 8·0% (7·6 to 8·4) 9·2% (7·1 to 11·7) 0·0
Iceland 5486 (5256 to 5722) 6931 (6189 to 7676) 5227 (5007 to 5451) 6603 (5896 to 7313) 8·6% (8·0 to 9·2) 10·3% (7·4 to 13·8) 0·0
Ireland 5673 (5413 to 5932) 8456 (7758 to 9225) 6362 (6071 to 6653) 9484 (8700 to 10 345) 6·8% (6·5 to 7·1) 9·1% (6·6 to 11·8) 0·0
Israel 3246 (3184 to 3307) 4174 (3854 to 4522) 3056 (2997 to 3114) 3930 (3629 to 4257) 7·1% (6·6 to 7·4) 8·1% (5·7 to 11·1) 0·0
Italy 2995 (2931 to 3061) 3160 (2924 to 3424) 3916 (3833 to 4003) 4132 (3823 to 4478) 8·7% (8·6 to 8·9) 10·6% (8·1 to 13·6) 0·0
Luxembourg 6246 (5877 to 6655) 6893 (6019 to 7849) 6436 (6055 to 6856) 7102 (6202 to 8087) 5·3% (5·0 to 5·6) 6·7% (4·9 to 8·9) 0·0
Malta 3174 (3081 to 3268) 4837 (4486 to 5211) 4803 (4663 to 4946) 7320 (6788 to 7886) 9·7% (8·6 to 10·6) 10·9% (7·4 to 15·5) 0·0
Monaco 3560 (3346 to 3779) 4719 (4118 to 5446) 3479 (3270 to 3693) 4612 (4025 to 5322) 1·7% (1·5 to 2·1) 2·0% (1·4 to 2·9) 0·0
Netherlands 5586 (5449 to 5735) 7722 (6885 to 8669) 6217 (6065 to 6382) 8594 (7662 to 9648) 10·3% (10·0 to 10·6) 13·6% (9·5 to 18·7) 0·0
Norway 7352 (7176 to 7537) 8329 (7576 to 9223) 7013 (6845 to 7189) 7945 (7227 to 8798) 10·4% (10·2 to 10·7) 12·6% (10·1 to 15·6) 0·0
Portugal 2187 (2117 to 2260) 2389 (2141 to 2685) 3350 (3243 to 3462) 3659 (3281 to 4113) 9·1% (8·8 to 9·4) 10·6% (8·2 to 13·6) 0·0
San Marino 3393 (3249 to 3540) 3944 (3644 to 4282) 4612 (4417 to 4812) 5361 (4953 to 5821) 7·2% (6·9 to 7·5) 8·5% (6·6 to 11·1) 0·0
Spain 2801 (2731 to 2868) 3313 (3063 to 3708) 3985 (3884 to 4079) 4712 (4357 to 5274) 9·1% (8·9 to 9·4) 12·3% (9·5 to 15·8) 0·0
(Table 1 continues on next page)
Articles
6 www.thelancet.com   Published online September 22, 2021   https://doi.org/10.1016/S0140-6736(21)01258-7
Health spending per 
person, 2019 (US$)
Projected health 
spending per person, 
2050 (2020 US$)
Health spending per 
person, 2019 ($PPP)
Projected health 
spending per person, 
2050 ($PPP)
Total health 
spending per GDP, 
2019
Total health 








(Continued from previous page)
Sweden 5898 (5692 to 6117) 8016 (7268 to 8874) 6149 (5933 to 6376) 8356 (7577 to 9250) 10·8% (10·4 to 11·3) 12·9% (9·1 to 17·6) 0·0
Switzerland 10 203 (10 057 to 10 351) 14 239 (12 827 to 15 690) 8521 (8398 to 8644) 11 891 (10 712 to 13 103) 11·6% (11·1 to 11·9) 17·0% (11·9 to 23·5) 0·0
UK 4392 (4329 to 4457) 5279 (4863 to 5702) 4960 (4888 to 5033) 5962 (5492 to 6439) 10·1% (9·9 to 10·3) 12·3% (9·9 to 14·9) 0·0
Latin America and Caribbean
Andean Latin America
Bolivia 233 (213 to 254) 336 (299 to 378) 585 (536 to 639) 845 (752 to 949) 6·4% (5·8 to 7·0) 8·5% (5·9 to 12·1) 0·0
Ecuador 483 (455 to 512) 684 (600 to 771) 963 (907 to 1022) 1366 (1198 to 1540) 8·0% (7·5 to 8·5) 11·0% (7·6 to 15·4) 0·0




972 (925 to 1024) 1381 (1160 to 1608) 1281 (1219 to 1349) 1820 (1528 to 2119) 5·6% (5·3 to 5·9) 7·9% (5·8 to 10·7) 0·0
The Bahamas 2191 (2111 to 2270) 3238 (2932 to 3572) 2468 (2377 to 2557) 3646 (3302 to 4022) 6·2% (6·0 to 6·5) 10·1% (7·4 to 13·5) 0·0
Barbados 1126 (1074 to 1182) 1104 (1023 to 1205) 1020 (973 to 1071) 1000 (927 to 1091) 6·2% (5·9 to 6·5) 6·4% (5·0 to 8·4) 0·0
Belize 283 (258 to 309) 450 (346 to 551) 431 (394 to 471) 686 (527 to 841) 6·0% (5·4 to 6·6) 8·1% (5·6 to 11·7) 0·0
Bermuda 8049 (7007 to 9277) 10 721 (8170 to 13 824) 5686 (4950 to 6553) 7574 (5771 to 9765) 6·7% (5·0 to 9·2) 12·1% (7·6 to 18·3) 0·0
Cuba 1170 (1090 to 1255) 1745 (1549 to 1936) 2863 (2667 to 3071) 4268 (3790 to 4735) 13·1% (11·7 to 14·7) 20·3% (14·1 to 28·4) 0·0
Dominica 431 (403 to 460) 466 (391 to 550) 676 (632 to 722) 731 (613 to 863) 5·1% (4·8 to 5·5) 5·1% (3·8 to 6·6) 0·0
Dominican 
Republic
446 (416 to 476) 715 (600 to 847) 1124 (1048 to 1200) 1804 (1514 to 2137) 5·7% (5·3 to 6·2) 7·6% (5·1 to 10·9) 0·0
Grenada 515 (483 to 551) 650 (560 to 766) 863 (808 to 923) 1088 (937 to 1283) 4·7% (4·4 to 5·1) 5·1% (3·6 to 6·9) 0·0
Guyana 323 (301 to 346) 542 (422 to 692) 648 (604 to 694) 1087 (847 to 1390) 4·4% (3·9 to 5·0) 5·1% (3·6 to 7·5) 0·0
Haiti 47 (43 to 53) 73 (64 to 84) 111 (100 to 124) 171 (151 to 199) 5·3% (3·0 to 7·5) 7·6% (3·8 to 12·6) 0·0
Jamaica 365 (337 to 393) 598 (509 to 698) 715 (660 to 769) 1170 (996 to 1366) 6·7% (6·0 to 7·3) 12·0% (8·3 to 16·8) 0·0
Puerto Rico 1286 (1138 to 1459) 1626 (1385 to 1890) 1496 (1323 to 1697) 1890 (1611 to 2198) 3·9% (3·4 to 4·5) 5·3% (3·8 to 7·2) 0·0
Saint Kitts and 
Nevis
1026 (967 to 1086) 1457 (1293 to 1651) 1415 (1332 to 1497) 2008 (1782 to 2276) 5·2% (4·8 to 5·7) 5·7% (4·3 to 7·3) 0·0




359 (334 to 387) 510 (451 to 576) 626 (583 to 675) 890 (788 to 1005) 4·7% (4·4 to 5·1) 6·5% (4·7 to 8·7) 0·0
Suriname 408 (381 to 438) 610 (501 to 746) 1420 (1324 to 1524) 2121 (1742 to 2595) 8·2% (7·6 to 8·8) 12·0% (8·1 to 17·1) 0·0
Trinidad and 
Tobago
1145 (1093 to 1203) 1392 (1262 to 1530) 1836 (1752 to 1929) 2232 (2022 to 2452) 6·6% (6·3 to 7·0) 8·1% (6·1 to 10·6) 0·0
Virgin Islands 969 (825 to 1133) 1132 (931 to 1375) 969 (825 to 1133) 1132 (931 to 1375) 2·4% (2·0 to 2·9) 2·7% (1·9 to 3·8) 0·0
Central Latin America
Colombia 447 (429 to 468) 810 (714 to 917) 1214 (1165 to 1270) 2198 (1939 to 2490) 7·8% (7·5 to 8·2) 12·7% (8·8 to 17·9) 0·0
Costa Rica 1083 (1061 to 1105) 1682 (1530 to 1869) 1798 (1762 to 1835) 2792 (2541 to 3104) 8·7% (8·6 to 8·9) 13·0% (9·3 to 17·7) 0·0
El Salvador 322 (299 to 347) 508 (452 to 572) 707 (657 to 764) 1116 (994 to 1258) 7·7% (7·1 to 8·3) 10·9% (8·2 to 14·1) 0·0
Guatemala 308 (291 to 326) 461 (420 to 501) 601 (567 to 636) 899 (820 to 977) 6·9% (6·3 to 7·4) 8·4% (6·5 to 10·7) 0·0
Honduras 187 (173 to 203) 283 (245 to 331) 429 (396 to 465) 650 (562 to 759) 7·1% (6·5 to 7·7) 8·3% (5·6 to 11·5) 0·0
Mexico 502 (482 to 525) 619 (572 to 671) 1171 (1124 to 1223) 1441 (1332 to 1564) 5·6% (5·4 to 5·8) 6·6% (5·0 to 8·2) 0·0
Nicaragua 169 (153 to 186) 262 (228 to 297) 501 (454 to 551) 777 (678 to 881) 8·7% (7·9 to 9·6) 12·5% (8·9 to 17·2) 1·3
Panama 1103 (1075 to 1128) 1631 (1464 to 1813) 2353 (2293 to 2406) 3479 (3121 to 3866) 7·1% (6·9 to 7·2) 8·8% (6·1 to 12·3) 0·0
Venezuela* 94 (84 to 104) 80 (68 to 93) 230 (206 to 255) 196 (166 to 228) 3·7% (3·0 to 4·5) 3·9% (2·5 to 5·6) 0·0
Tropical Latin America
Brazil 639 (598 to 682) 1099 (950 to 1266) 1443 (1350 to 1540) 2480 (2144 to 2858) 9·3% (8·7 to 9·9) 14·8% (10·1 to 21·0) 0·2
Paraguay 380 (357 to 404) 750 (678 to 830) 968 (908 to 1029) 1909 (1727 to 2114) 7·2% (6·8 to 7·7) 11·1% (7·7 to 15·0) 0·0
(Table 1 continues on next page)
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North Africa and Middle East
Afghanistan 54 (49 to 58) 58 (53 to 64) 223 (205 to 243) 243 (221 to 265) 10·5% (9·3 to 11·8) 9·9% (6·6 to 14·2) 0·0
Algeria 231 (210 to 253) 308 (260 to 363) 765 (696 to 838) 1021 (862 to 1202) 6·4% (5·8 to 7·0) 9·0% (6·4 to 12·3) 0·0
Bahrain 1052 (1001 to 1103) 938 (793 to 1108) 2260 (2151 to 2369) 2015 (1705 to 2380) 4·6% (4·1 to 4·9) 6·2% (4·2 to 8·6) 0·0
Egypt 173 (162 to 183) 276 (248 to 306) 617 (580 to 655) 984 (884 to 1093) 5·2% (4·6 to 5·7) 5·9% (4·0 to 8·2) 0·0
Iran 675 (642 to 706) 890 (770 to 1014) 1112 (1059 to 1164) 1467 (1270 to 1671) 8·4% (7·7 to 9·1) 14·2% (10·2 to 19·1) 0·0
Iraq 185 (168 to 203) 322 (246 to 409) 415 (378 to 455) 723 (552 to 917) 3·6% (3·3 to 4·0) 5·0% (3·1 to 7·9) 0·0
Jordan 306 (284 to 331) 475 (403 to 560) 734 (679 to 792) 1137 (966 to 1341) 6·9% (6·4 to 7·4) 10·3% (7·3 to 14·2) 0·0
Kuwait 1453 (1317 to 1607) 1098 (906 to 1332) 2724 (2469 to 3013) 2059 (1699 to 2497) 5·4% (4·7 to 6·3) 7·6% (5·0 to 11·3) 0·0
Lebanon 395 (367 to 425) 436 (382 to 501) 1663 (1547 to 1789) 1837 (1608 to 2109) 10·7% (10·0 to 11·5) 12·7% (9·0 to 17·3) 0·0
Libya 798 (683 to 930) 658 (448 to 924) 1155 (988 to 1344) 944 (648 to 1336) 9·0% (3·5 to 18·1) 10·3% (3·2 to 24·4) 0·0
Morocco 176 (165 to 187) 295 (263 to 331) 429 (401 to 455) 719 (642 to 808) 5·1% (4·7 to 5·6) 7·1% (4·9 to 9·9) 0·0
Oman 612 (560 to 667) 679 (528 to 860) 1272 (1165 to 1387) 1410 (1098 to 1788) 4·1% (3·5 to 4·7) 5·4% (3·4 to 7·9) 0·0
Palestine 395 (368 to 425) 742 (638 to 859) 190 (177 to 205) 357 (307 to 414) 10·6% (9·7 to 11·5) 14·3% (9·8 to 19·7) 0·0
Qatar 1731 (1554 to 1923) 2790 (1869 to 4115) 3017 (2707 to 3351) 4861 (3256 to 7169) 3·2% (2·8 to 3·5) 9·4% (5·5 to 15·6) 0·0
Saudi Arabia 1364 (1285 to 1444) 2161 (1901 to 2437) 3223 (3035 to 34117) 5107 (4491 to 5758) 6·5% (6·1 to 6·9) 15·4% (10·4 to 22·1) 0·0
Sudan 49 (44 to 55) 65 (57 to 75) 252 (226 to 280) 334 (289 to 382) 5·1% (3·3 to 6·7) 4·6% (2·6 to 6·7) 0·0
Syria 44 (39 to 50) 57 (50 to 64) 1046 (925 to 1204) 1353 (1185 to 1542) 3·6% (3·1 to 4·2) 4·4% (3·0 to 6·5) 0·0
Tunisia 281 (260 to 303) 434 (393 to 477) 884 (820 to 953) 1365 (1237 to 1504) 7·8% (7·2 to 8·4) 10·9% (7·6 to 15·2) 0·0
Turkey 359 (336 to 382) 552 (448 to 665) 1316 (1231 to 1400) 2026 (1644 to 2438) 4·4% (4·1 to 4·6) 6·3% (4·1 to 9·0) 0·0
United Arab 
Emirates
1751 (1675 to 1824) 1353 (839 to 2357) 3203 (3065 to 3338) 2476 (1535 to 4312) 4·7% (4·3 to 5·2) 9·4% (4·9 to 18·6) 0·0
Yemen 35 (30 to 40) 46 (39 to 54) 105 (91 to 121) 137 (117 to 161) 5·4% (4·0 to 7·4) 5·5% (3·6 to 8·3) 0·0
South Asia
Bangladesh 48 (43 to 54) 76 (67 to 86) 129 (115 to 145) 204 (180 to 230) 2·6% (2·3 to 3·0) 2·7% (1·8 to 3·8) 0·3
Bhutan 90 (82 to 98) 195 (155 to 241) 315 (288 to 345) 684 (545 to 846) 2·6% (2·4 to 2·8) 3·4% (2·2 to 5·1) 12·2
India 75 (67 to 85) 150 (132 to 173) 253 (223 to 286) 504 (441 to 578) 3·5% (3·1 to 4·0) 4·3% (2·9 to 6·2) 0·0
Nepal 58 (54 to 64) 105 (93 to 120) 188 (173 to 205) 336 (298 to 386) 5·3% (4·8 to 5·8) 5·9% (4·1 to 8·3) 0·0
Pakistan 43 (40 to 46) 82 (70 to 94) 158 (146 to 170) 298 (256 to 343) 3·0% (2·8 to 3·3) 3·7% (2·5 to 5·2) 0·0
Southeast Asia, east Asia, and Oceania
East Asia
China 563 (531 to 594) 1470 (1289 to 1657) 893 (843 to 943) 2334 (2046 to 2631) 5·3% (5·0 to 5·6) 8·3% (5·6 to 11·7) 0·0








577 (492 to 668) 711 (603 to 828) 577 (492 to 668) 711 (603 to 828) 4·9% (4·0 to 5·8) 5·9% (3·9 to 8·4) 0·0




147 (131 to 164) 249 (211 to 290) 131 (117 to 147) 222 (189 to 260) 3·9% (3·3 to 4·6) 5·4% (3·7 to 7·5) 0·0
Fiji 195 (182 to 208) 304 (269 to 340) 498 (466 to 531) 777 (689 to 870) 3·4% (2·9 to 4·0) 4·5% (3·2 to 6·1) 0·0
Guam 953 (826 to 1099) 1164 (1000 to 1352) 953 (826 to 1099) 1164 (1000 to 1352) 2·6% (2·2 to 3·1) 3·1% (2·3 to 4·2) 0·0
Kiribati 200 (182 to 219) 255 (209 to 317) 259 (236 to 284) 331 (272 to 411) 12·0% (10·9 to 13·1) 14·0% (9·9 to 19·5) 0·0
Marshall 
Islands
536 (499 to 580) 837 (683 to 1036) 499 (464 to 539) 778 (635 to 964) 12·4% (10·4 to 14·2) 15·4% (11·1 to 21·3) 0·0
(Table 1 continues on next page)
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Nauru 1237 (1134 to 1342) 840 (653 to 1124) 1387 (12571to 1504) 941 (732 to 1260) 11·9% (6·9 to 17·1) 7·8% (3·7 to 14·1) 0·0
Niue 2273 (1858 to 27652 2897 (1734 to 4478) 849 (694 to 1028) 1082 (648 to 1673) 11·9% (9·4 to 15·1) 11·9% (6·6 to 20·3) 0·0
Northern 
Mariana Islands
523 (443 to 610) 651 (509 to 841) 523 (443 to 610) 651 (509 to 841) 2·2% (1·8 to 2·7) 3·5% (2·3 to 5·2) 0·0
Palau 1827 (1742 to 1916) 3046 (2651 to 3482) 1817 (1733 to 1907) 3031 (2638 to 3464) 11·3% (10·7 to 11·8) 16·2% (12·0 to 21·4) 0·0
Papua New 
Guinea
73 (66 to 82) 104 (87 to 126) 106 (95 to 119) 151 (127 to 183) 2·6% (2·4 to 3·0) 3·0% (2·1 to 4·2) 2·1
Samoa 235 (217 to 253) 331 (291 to 378) 319 (294 to 344) 450 (396 to 514) 5·3% (4·7 to 5·8) 7·3% (5·2 to 10·2) 0·0
Solomon 
Islands
112 (99 to 128) 176 (102 to 300) 116 (102 to 132) 182 (105 to 310) 4·8% (3·9 to 6·1) 5·8% (2·9 to 11·1) 0·0
Tokelau 1492 (1274 to 1751) 2679 (2229 to 3236) 3074 (2625 to 3608) 5520 (4592 to 6666) 23·1% (19·6 to 27·2) 26·3% (17·8 to 38·5) 0·0
Tonga 240 (224 to 256) 330 (297 to 367) 290 (272 to 310) 399 (360 to 444) 4·7% (4·3 to 5·1) 4·8% (3·8 to 6·0) 88·3
Tuvalu 757 (693 to 833) 1010 (799 to 1307) 835 (763 to 918) 1114 (881 to 1441) 19·0% (16·9 to 21·3) 19·8% (13·2 to 28·2) 0·0
Vanuatu 100 (88 to 114) 148 (104 to 212) 92 (81 to 105) 136 (95 to 195) 3·1% (2·7 to 3·5) 3·3% (2·0 to 5·2) 0·0
Southeast Asia
Cambodia 83 (75 to 91) 108 (97 to 120) 233 (212 to 257) 305 (275 to 340) 5·0% (4·6 to 5·6) 4·5% (3·2 to 6·1) 0·0
Indonesia 122 (115 to 131) 283 (237 to 336) 373 (351 to 399) 864 (724 to 1028) 3·0% (2·8 to 3·2) 4·8% (3·3 to 7·0) 0·0
Laos 63 (60 to 66) 89 (81 to 98) 202 (193 to 211) 286 (260 to 314) 2·5% (2·1 to 2·9) 2·1% (1·4 to 3·0) 0·2
Malaysia 448 (422 to 477) 947 (844 to 1070) 1200 (1130 to 1277) 2537 (2261 to 2866) 4·1% (3·8 to 4·3) 6·5% (4·5 to 9·2) 0·0
Maldives 1164 (1085 to 1245) 1712 (1343 to 2146) 2145 (2000 to 2293) 3153 (2475 to 3953) 9·1% (6·9 to 10·9) 12·2% (7·2 to 18·9) 0·0
Mauritius 671 (632 to 714) 1232 (1113 to 1362) 1553 (1463 to 1652) 2853 (2576 to 3152) 6·4% (6·0 to 6·8) 9·3% (6·5 to 12·7) 0·0
Myanmar 60 (56 to 63) 109 (99 to 120) 233 (220 to 246) 424 (385 to 468) 4·4% (4·0 to 4·8) 4·8% (3·2 to 6·8) 0·0
Philippines 156 (142 to 172) 259 (228 to 295) 396 (362 to 437) 659 (580 to 751) 4·3% (3·8 to 4·8) 5·6% (3·8 to 7·6) 0·0
Seychelles 673 (642 to 701) 935 (791 to 1103) 1440 (1376 to 1502) 2003 (1694 to 2362) 4·7% (4·4 to 4·9) 6·1% (4·1 to 9·0) 0·0
Sri Lanka 156 (146 to 167) 234 (211 to 261) 555 (519 to 593) 830 (749 to 926) 4·0% (3·7 to 4·3) 4·4% (3·1 to 6·0) 1·8
Thailand 307 (286 to 330) 595 (517 to 680) 759 (708 to 818) 1475 (1282 to 1686) 3·9% (3·6 to 4·2) 6·8% (4·7 to 9·6) 0·0
Timor-Leste 82 (74 to 90) 97 (73 to 132) 226 (205 to 249) 269 (202 to 365) 6·5% (5·6 to 7·4) 5·1% (3·2 to 7·7) 0·0
Vietnam 167 (157 to 177) 288 (241 to 344) 512 (483 to 545) 884 (741 to 1056) 5·7% (4·4 to 6·9) 7·1% (4·3 to 10·7) 0·1
Sub-Saharan Africa
Central sub-Saharan Africa
Angola 57 (50 to 64) 94 (75 to 117) 195 (172 to 222) 326 (260 to 405) 2·7% (2·4 to 3·1) 3·2% (2·1 to 4·7) 0·0
Central African 
Republic
30 (28 to 33) 47 (41 to 56) 61 (56 to 66) 95 (83 to 113) 6·1% (5·6 to 6·6) 7·7% (5·6 to 10·4) 0·0
Congo 
(Brazzaville)
47 (43 to 51) 70 (58 to 86) 93 (86 to 102) 139 (115 to 172) 2·2% (1·9 to 2·6) 2·5% (1·7 to 3·6) 0·2
Democratic 
Republic of the 
Congo
20 (19 to 22) 25 (22 to 29) 43 (41 to 46) 54 (46 to 62) 4·0% (3·5 to 4·5) 4·3% (2·8 to 6·3) 0·0
Equatorial 
Guinea
222 (196 to 252) 507 (431 to 603) 554 (488 to 627) 1265 (1074 to 1504) 2·8% (2·5 to 3·2) 3·5% (2·1 to 5·5) 0·0
Gabon 245 (228 to 261) 452 (395 to 521) 541 (504 to 576) 997 (872 to 1151) 3·4% (3·1 to 3·6) 5·3% (3·8 to 7·3) 0·0
Eastern sub-Saharan Africa
Burundi 29 (27 to 31) 40 (35 to 47) 86 (80 to 93) 120 (103 to 141) 10·0% (8·8 to 11·2) 12·3% (8·7 to 16·8) 0·0
Comoros 83 (74 to 94) 112 (96 to 133) 187 (166 to 213) 252 (216 to 299) 5·6% (4·7 to 6·6) 6·2% (4·2 to 8·7) 0·0
Djibouti 54 (47 to 61) 72 (58 to 87) 88 (77 to 100) 119 (96 to 144) 1·6% (1·4 to 1·9) 1·9% (1·2 to 2·8) 0·0
Eritrea 15 (13 to 17) 20 (17 to 23) 46 (42 to 52) 62 (54 to 72) 2·5% (2·2 to 2·8) 2·4% (1·7 to 3·3) 0·0
Ethiopia 26 (24 to 28) 38 (33 to 43) 75 (69 to 80) 107 (94 to 122) 3·0% (2·5 to 3·4) 2·6% (1·7 to 3·7) 0·2
Kenya 103 (95 to 112) 176 (152 to 204) 248 (229 to 270) 423 (367 to 492) 5·2% (4·6 to 5·9) 6·4% (4·4 to 8·8) 0·1
Madagascar 22 (19 to 25) 31 (26 to 35) 70 (61 to 79) 98 (85 to 113) 4·0% (3·6 to 4·5) 5·4% (3·9 to 7·3) 0·0
(Table 1 continues on next page)
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from one agency to another. Although OECD CRS 
completeness has improved over time, in earlier years 
(for this study, 1990 to 1996 especially) the data were 
less complete; thus, we used adjusted commitment 
data from the Development Assistance Committee 
tables to estimate disbursements. We also estimated 
the expenses asso ciated with administering loans and 
grants.
Estimating development assistance for health for 
COVID-19
We developed a separate method for estimating 
development assistance for health for COVID-19 because 
much of the project-level data used as input for the 
historical development assistance for health estimates do 
not extend to 2020, and therefore do not include resources 
disbursed in response to COVID-19. Likewise, budget and 
Health spending per 
person, 2019 (US$)
Projected health 
spending per person, 
2050 (2020 US$)
Health spending per 
person, 2019 ($PPP)
Projected health 
spending per person, 
2050 ($PPP)
Total health 
spending per GDP, 
2019
Total health 








(Continued from previous page)
Malawi 43 (40 to 45) 51 (43 to 60) 107 (101 to 113) 126 (108 to 149) 9·8% (8·9 to 11·0) 7·9% (5·4 to 10·9) 0·0
Mozambique 36 (34 to 38) 43 (35 to 54) 100 (95 to 106) 121 (97 to 151) 7·4% (7·0 to 7·9) 4·9% (3·3 to 7·3) 0·0
Rwanda 53 (47 to 59) 96 (76 to 119) 153 (137 to 172) 278 (221 to 344) 6·6% (5·8 to 7·5) 8·6% (5·7 to 12·5) 0·0
Somalia 7 (6 to 8) 9 (8 to 11) 21 (19 to 23) 28 (24 to 33) 5·4% (4·7 to 6·2) 6·4% (4·9 to 8·5) 0·0
South Sudan 29 (27 to 30) 34 (30 to 41) 83 (79 to 88) 100 (88 to 119) 9·3% (4·3 to 15·8) 11·1% (4·3 to 20·5) 0·0
Tanzania 40 (37 to 43) 54 (42 to 71) 103 (95 to 111) 140 (108 to 183) 3·7% (3·1 to 4·3) 3·6% (2·3 to 5·4) 0·0
Uganda 46 (43 to 50) 55 (48 to 62) 131 (121 to 142) 154 (135 to 176) 5·7% (4·5 to 7·6) 4·3% (2·6 to 6·8) 0·0
Zambia 62 (58 to 67) 76 (59 to 102) 205 (191 to 222) 252 (193 to 336) 5·6% (5·1 to 6·1) 5·1% (3·4 to 7·4) 0·1
Southern sub-Saharan Africa
Botswana 464 (436 to 494) 1257 (1124 to 1392) 1144 (1073 to 1218) 3097 (2768 to 3429) 6·2% (5·7 to 6·6) 11·7% (8·0 to 16·4) 0·0
Eswatini 226 (215 to 238) 340 (296 to 389) 593 (563 to 625) 893 (775 to 1021) 6·4% (6·0 to 6·8) 6·6% (4·4 to 9·0) 0·0
Lesotho 125 (115 to 136) 220 (188 to 255) 390 (358 to 425) 686 (586 to 795) 13·0% (11·9 to 14·2) 14·7% (10·1 to 20·9) 0·0
Namibia 410 (382 to 441) 806 (702 to 930) 964 (899 to 1039) 1897 (1652 to 2190) 9·4% (8·7 to 10·1) 15·0% (10·6 to 20·4) 0·0
South Africa 478 (448 to 513) 766 (666 to 890) 1202 (1128 to 1290) 1927 (1675 to 2238) 9·1% (8·5 to 9·8) 14·2% (10·8 to 18·2) 0·0
Zimbabwe 75 (69 to 83) 108 (90 to 130) 211 (194 to 231) 303 (253 to 364) 7·1% (6·5 to 7·8) 8·3% (5·8 to 11·5) 0·0
Western sub-Saharan Africa
Benin 29 (26 to 32) 42 (37 to 49) 79 (72 to 86) 116 (101 to 133) 2·2% (2·1 to 2·5) 2·2% (1·6 to 3·0) 0·2
Burkina Faso 41 (39 to 44) 70 (64 to 78) 119 (113 to 125) 202 (183 to 224) 5·1% (4·9 to 5·4) 5·8% (4·1 to 8·2) 0·0
Cameroon 49 (42 to 56) 77 (65 to 90) 121 (104 to 139) 192 (161 to 223) 3·1% (2·7 to 3·6) 3·2% (2·4 to 4·2) 0·0
Cape Verde 183 (170 to 196) 325 (261 to 386) 380 (354 to 407) 676 (542 to 802) 5·0% (4·7 to 5·4) 7·1% (5·0 to 9·6) 0·0
Chad 28 (25 to 33) 33 (28 to 40) 71 (62 to 83) 85 (71 to 101) 4·3% (3·7 to 4·9) 3·8% (2·8 to 5·3) 0·0
Côte d’Ivoire 72 (66 to 79) 110 (94 to 129) 170 (155 to 186) 259 (221 to 302) 5·3% (2·6 to 10·6) 6·8% (3·0 to 14·0) 0·0
The Gambia 39 (38 to 41) 49 (44 to 55) 118 (113 to 124) 147 (132 to 166) 5·0% (4·8 to 5·3) 4·6% (3·4 to 6·2) 0·0
Ghana 72 (66 to 81) 121 (104 to 142) 189 (171 to 210) 316 (271 to 371) 3·7% (2·9 to 5·1) 4·6% (3·0 to 7·3) 0·0
Guinea 50 (45 to 55) 81 (71 to 93) 124 (112 to 136) 201 (174 to 230) 4·3% (3·6 to 5·3) 4·4% (3·1 to 6·2) 0·0
Guinea-Bissau 58 (55 to 62) 78 (71 to 85) 178 (167 to 190) 238 (215 to 259) 7·8% (6·9 to 8·6) 7·4% (5·3 to 10·0) 0·0
Liberia 66 (62 to 70) 94 (81 to 114) 154 (145 to 164) 222 (191 to 267) 11·3% (8·5 to 15·7) 13·7% (8·2 to 23·1) 0·1
Mali 30 (27 to 32) 39 (34 to 44) 80 (74 to 87) 105 (92 to 118) 3·0% (2·3 to 3·6) 2·5% (1·6 to 3·8) 0·0
Mauritania 65 (59 to 71) 93 (81 to 106) 210 (192 to 231) 301 (263 to 342) 3·7% (3·2 to 4·2) 3·7% (2·7 to 5·2) 0·0
Niger 30 (29 to 32) 37 (34 to 42) 71 (67 to 75) 87 (78 to 97) 5·5% (5·2 to 5·8) 5·5% (3·9 to 7·4) 0·0
Nigeria 81 (73 to 90) 106 (91 to 123) 192 (173 to 213) 249 (215 to 290) 3·5% (3·2 to 3·9) 3·4% (2·5 to 4·8) 0·1
São Tomé and 
PrÍncipe
117 (109 to 125) 183 (134 to 258) 234 (219 to 252) 367 (268 to 518) 5·6% (5·3 to 6·0) 6·3% (4·0 to 9·9) 0·0
Senegal 66 (60 to 74) 90 (80 to 102) 158 (142 to 176) 215 (191 to 243) 4·4% (4·0 to 4·9) 4·4% (3·2 to 5·9) 0·1
Sierra Leone 73 (66 to 81) 110 (95 to 128) 241 (217 to 269) 363 (312 to 422) 13·4% (12·0 to 14·9) 14·9% (10·5 to 20·5) 0·4
Togo 40 (37 to 44) 62 (54 to 71) 96 (88 to 105) 146 (128 to 169) 5·2% (3·9 to 6·4) 5·9% (3·7 to 8·4) 0·0
Estimates in parentheses are 95% uncertainty intervals. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. GDP=gross domestic product. *Estimates for Venezuela are presented as 2014 USD. 
$PPP=2020 purchasing-power parity-adjusted US$.
Table 1: Health spending and development assistance for health in 2019 and 2050 by region
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commitment data made before 2020 do not include the 
response to the pandemic. To adjust our 2020 development 
assistance estimates and include disbursements related to 
COVID-19, we extracted project data on commitments 
and disbursements from a diverse set of databases. Our 
primary focus was on the UN Office of Humanitarian 
Assistance financial tracking service (UNOCHA) and the 
International Aid Transparency Initiative (IATI). We relied 
on UNOCHA for data on non-governmental organi-
sations; UNICEF; the UN Population Fund; and bilateral 
development agencies for the United Arab Emirates, 
Switzerland, Italy, and New Zealand. We relied on IATI for 
data on bilateral develop ment agencies for Australia, 
Belgium, Canada, Denmark, Finland, France, Germany, 
Italy, the Netherlands, New Zealand, Norway, South Korea, 
Spain, Sweden, Switzerland, the UK, the USA, and 
the European Commission. We obtained data through 
correspondence for regional banks and other inter-
national agencies. For US foundations, we extracted 
commitment estimates from Candid. We extracted 
relevant data directly from organisations’ online databases 
for the Bill & Melinda Gates Foundation; the Global Fund; 
Gavi, the Vaccine Alliance; WHO; the Pan American 
Health Organization; the World Bank; and regional 
development banks. For each agency, we extracted data on 
all 2020 project commitments and disbursements, as 
available. Data on commitments captured the resource 
allocation committed towards project activities that were 
generally available in project budget documents. 
Disbursements captured the value of project resources 
that had been transferred to implementing agencies to 
finance project activities.
We used the information available to determine 
whether projects were new grants or previous grants 
repurposed to COVID-19 projects. UNOCHA data 
designated whether resources were new or not. For IATI, 
we assumed that COVID-19 projects starting before 
2020 were repurposed. For data received from 
correspondence or extracted from online databases, we 
contacted the respective agencies and searched their 
websites for more information. We included all research 
and development funding that went through international 
development agencies (appendix pp 91–92).
The approach used for each disbursing agency was 
specific to the data extracted and is detailed in the 
appendix (pp 92–106). Briefly, the general method was to 
use keywords to isolate COVID-19-relevant projects 
from each agency’s database. We then examined these 
projects for completeness of information and adjusted the 
data to ensure that the estimate used was as precise 
as possible and could be compared between agencies. 
For instance, for projects with commitment estimates 
but without disbursement estimates, we calculated the 
average commitment-to-disbursement ratio for projects 
with complete data (for that development agency if 
possible) and multiplied the mean of those disbursement 
ratios by the commitment estimates for the projects 
without disbursement information. This commitment-to-
disbursement ratio captures the propor tion of committed 
funds that were estimated to have been disbursed in 2020. 
Next, we used a keyword search on project descriptions to 
disaggregate the estimated COVID-19 disbursements into 
eight COVID-19 programme areas: country-level coordi-
nation (planning, monitoring, and evaluation; risk 
communication; community engage ment; and travel 
restrictions); surveillance, rapid-response teams, and case 
investigation; national laboratories and testing; infection 
prevention and personal protective equipment; treatment; 
supply chain and logistics; main taining other essential 
health services and systems; and research and development 
for vaccines and other thera peutics (from a development 
Figure 1: Development assistance for health by health focus area, 1990–2020
HSS/SWAps=health system strengthening and sector-wide approaches. *Other captures development assistance 
for health for which we have health focus area information but is not identified as being allocated to any of the 
health focus areas listed. Health assistance for which we have no health focus area information is designated as 
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agency). These programme areas were developed based on 
a review of the data and literature.
Finally, we reviewed the development agencies to 
identify any instances of double counting of the same 
resources across agencies. To do this, we reviewed 
income and recipient agency data for each of the 
disbursing channels that we tracked and excluded 
disbursements to recipient agencies that we tracked 
Figure 2: Development assistance for health, 1990–2020
(A) Development assistance for health by source of funding. (B) Development assistance for health by channel of assistance. (C) Development assistance for other infectious disease programme areas. 
(D) Development assistance for health systems strengthening programmes. CEPI=Coalition for Epidemic Preparedness Innovations. GAVI=Gavi, the Vaccine Alliance. HSS/SWAps=health systems 
strengthening and sector-wide approaches. IBRD=International Bank for Reconstruction and Development. NGO=non-governmental organisation. PAHO=Pan American Health Organization. 
UNFPA=UN Population Fund. *Other captures development assistance for health for which we have source information but is not identified as being allocated to any of the health focus areas listed. 
Health assistance for which we have no health focus area information is designated as unassigned. †2019 and 2020 disbursement estimates are preliminary. ‡Regional development banks include the 
African Development Bank, the Asian Development Bank, and the Inter-American Development Bank. §Other bilateral development agencies include Austria, Belgium, Denmark, Finland, Greece, 
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separately as disbursing agencies. We typically kept the 
disbursed resources with the development agency that 
was closest in the process to the final recipient country. 
This review ensured that we counted each disbursement 
from the source agency, to ultimate disbursing agency, to 
the final recipient only once.
Estimating future health spending, 2019–50
We estimated GDP; general government spending 
(across all sectors); government, out-of-pocket, and 
prepaid private health spending; and total development 
assistance for health provided and received until 2050. 
The methods used for these projections draw heavily 
from our previous research, with the key change being 
the updating of the retrospective estimates on which 
these projections are based.5,32,33 Because this research 
draws from a diverse set of underlying input data, 
updates to these data have cascading effects and affect all 
of the projections.
We generated these projections by use of ensemble 
modelling techniques, such that the estimates are the 
mean of 1000 estimated projections from a broad set of 
models. We defined model selection by out-of-sample 
validation. This selection was country-specific and year-
specific. We completed projections sequentially so that 
previously projected values could be used as covariates 
and for bounding other models. We forecasted GDP 
per working-age adult aged 20–64 years from 2022 to 2050, 
with 2020 and 2021 estimates drawing on methods that 
focused on estimating economic growth sensitive to 
COVID-19 projects (appendix p 8). We forecasted general 
government spending from 2020 to 2050 (as the 
retrospective estimates extend to 2019). We modelled 
development assistance for health as a proportion of 
the donor country’s general government spending, or, 
for private donors, on the basis of AutoRegressive 
Integrated Moving Average modelling techniques 
from 2021 to 2050 (as the retrospective estimates 
extend to 2020).
We aggregated total development assistance for health 
provided across sources and used a separate model to 
project the proportion of total development assistance 
for health that each recipient was expected to receive 
from 2019 to 2050 (as these retrospective data extend 
to 2018). We also modelled when countries are projected 
to transition to being high-income and are no longer 
eligible to receive development assistance for health. We 
projected government health spending as a share of 
general government spending, prepaid private health 
spending as a share of GDP, and out-of-pocket health 
spending as a share of GDP from 2019 to 2050 (as the 
retrospective data extend to 2018). To capture increased 
government spending in response to COVID-19, we 
checked whether our 2020 estimates of government 
health spending increased by at least the estimates made 
by the IMF October 2020 Fiscal Monitor of previously 
unanticipated government health spending. Countries 
that had year-over-year spending increases in 2020 that 
were less than estimated increase reported in the Fiscal 
Monitor were adjusted upward proportionally.
All projections incorporated several types of uncer-
tainty. We used ensemble modelling techniques to 
propagate model uncertainty. We took draws of the 
variance-covariance matrix of each estimate’s model to 
propagate parameter uncertainty. Finally, we added a 
random walk residual to each projection to propagate 
fundamental uncertainty. We generated 95% UIs by 
taking the 2·5th and 97·5th percentile of the 1000 esti -
mated random draws.
Reporting
We report all the historical and future spending estimates 
in inflation-adjusted 2020 US$ and 2020 US$ per capita, 
and in purchasing-power parity-adjusted US$ per capita 
and as a proportion of GDP. For the development 
assistance for health estimates, we adjusted for inflation 
by taking disbursements in nominal US$ in the year of 
disbursements and using US GDP deflators from the 
IMF World Economic Outlook database to convert the 
series to constant 2020 US$. For the historical and future 
global health spending estimates, we used country-
specific exchange rate data and deflator series from IMF 
to convert the series to constant 2020 US$. We report all 
Figure 3: Distribution of development assistance for health for COVID-19 by 
programme area, recipient region, and income group, 2020
(A) Flow of development assistance for health disbursements from source to 
channel to programme area for COVID-19. Data are in million (m) or billion (b) 
2020 US$. (B) Percentage of disbursed development assistance for health for 
COVID (excluding global initiatives) and percentage of total deaths from 
COVID-19 by GBD super-region. (C) Percentage of disbursed development 
assistance for health for COVID-19 (excluding global initiatives) and percentage 
of total deaths from COVID-19 by World Bank income group. The COVID-19 
burden is represented by the percentage of total COVID-19 deaths in 2020 for 
lower-middle-income countries only, as high-income countries to not receive 
development assistance. CEPI=Coalition for Epidemic Preparedness Innovations. 
DAC=Development Assistance Committee. GAVI=Gavi, the Vaccine Alliance. 
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study 
HSS/SWAps=health systems strengthening and sector-wide approaches. 
IBRD=International Bank for Reconstruction and Development. NGO=non-
governmental organisation. PAHO=Pan American Health Organization. 
UNFPA=UN Population Fund. *Other non-DAC governments include 
Afghanistan, Angola, Argentina, Azerbaijan, Bangladesh, Bhutan, Brazil, Brunei, 
Bulgaria, Côte d’Ivoire, Cameroon, Central African Republic, Chad, China, 
Colombia, Croatia, Democratic Republic of the Congo, Egypt, Estonia, Ethiopia, 
Gabon, Guinea, India, Indonesia, Iran, Iraq, Jamaica, Jordan, Kenya, Kuwait, Latvia, 
Lebanon, Libya, Lithuania, Madagascar, Malaysia, Malta, Monaco, Myanmar, 
Nigeria, Oman, Pakistan, Palestine, Peru, Qatar, Romania, Russia, São Tomé and 
Príncipe, Saudi Arabia, Serbia, Singapore, South Africa, South Sudan, Sudan, 
Syria, Taiwan (province of China), Thailand, Togo, Turkey, Uganda, Ukraine, 
United Arab Emirates, Yemen, and Zimbabwe. †Other DAC governments include 
Australia, Austria, Belgium, Czechia, Denmark, Finland, Greece, Hungary, Iceland, 
Ireland, Italy, Luxembourg, the Netherlands, New Zealand, Norway, Poland, 
Portugal, Slovakia, Slovenia, South Korea, Spain, Sweden, and Switzerland. 
‡Development banks include the African Development Bank, the Asian 
Development Bank, and the Inter-American Development Bank. UN agencies 
include PAHO, UNAIDS, UNFPA, UNICEF, and Unitaid. §Country-level 
coordination includes planning, monitoring, and evaluations; risk 
communication and community engagement; and travel restrictions.
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spending estimates by 2019 Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD) super-region and 
2020 World Bank income groups.37 For these aggregates 
(and the global aggregate) the reported estimates provide 
information about a group as a whole, rather than the 
mean of the countries included in that group. For all 
tables and figures, the country income classifications 
were held constant at the 2020 reported level, irrespective 
of whether they changed groups. The time periods for 
each of the financing sources differs relative to the 
availability of the underlying data (development assis-
tance for health, 1990–2020; domestic health spending, 
1995–2018; and future health spending, 2019–50). These 
time periods provide a time series of health spending 
data that makes sure to leverage all available data. We 
completed all the analyses using Stata (versions 13 
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Role of the funding source
The funder of this study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
In 2019, total global health spending reached $8·8 trillion 
(95% UI 8·7–8·8) and was $1132 per person (1119–1143; 
table 1), with a wide variation in spending across 
geographical regions and country income groups. 
In 2019, high-income countries spent an estimated 
$5702 (95% UI 5638–5769) per person, with country-
specific spending ranging from $523 (443–610) 
per person in the Northern Mariana Islands to $11 345 
(11 114–11 578) per person in the USA. Across this income 
group, the most spending was from governments, which 
made up 61·4% (95% UI 60·9–62·0) of health spending, 
although countries such as the USA and Switzerland 
also relied substantially on prepaid private spending. 
Upper-middle-income countries spent $500 (484–517) 
per person on health, ranging from $94 (84–104) in 
Venezuela to $1492 (1274–1751) in Tokelau, and relied 
mostly on governments to finance their health spending. 
Lower-middle-income countries spent $90 (86–95) per 
person on health, ranging from $29 (26–32) in Benin to 
$395 (368–425) in Palestine, and relied mostly on out-of-
pocket spending to finance their health spending. In 
2019, low-income countries spent $36 (35–37) per person 
on health, ranging from $7 (6–8) in Somalia to $73 
(66–81) in Sierra Leone, and also relied mostly on out-of-
pocket spending. In 2019, development assistance for 
health to low-income and middle-income countries was 
$40·4 billion, or 0·5% (95% UI 0·5–0·5) of total global 
health spending. In 2019, development assistance for 
health made up 24·6% (24·0–25·1) of health spending 
in low-income countries and 3·2% (3·1–3·4) of health 
spending in lower-middle-income countries.
Between 1995 and 2019, inflation-adjusted health 
spending per person increased in 182 of the 204 countries 
and territories considered. For health spending for every 
country and year from 1995 to 2050, see the appendix 
(p 142). We estimate that global health spending will 
reach $14·3 trillion (95% UI 13·7–15·0) by 2050.
Between 2012 and 2019, development assistance for 
health contributions plateaued at an annualised rate 
of 1·2%. However, in 2020, total development assistance 
for health (including development assistance for health 
for COVID-19) amounted to $54·8 billion, a $14·0 billion 
(34·6%) increase from 2019. The increase is largely 
(96·5%) attributable to disbursements for the health 
response to COVID-19, which amassed $13·7 billion of 
health assistance (or 24·9% of total development 
assistance for health) in 2020 (figure 1). For year-on-year 
com parisons, we observed decreases in assistance tar-
geted toward reproductive and maternal health (–6·8%), 
tuberculosis (–5·5%), and malaria (–2·2%). Meanwhile, 
development assistance for sector-wide approaches and 
health system strengthening increased (8·8%). Of note 
is the small proportion of health systems strength-
ening resources (14·9% in 2020) that have been targeted 
towards pandemic preparedness.
Figure 2A shows the main sources of development 
assistance for health in 2020. Most of the funding came 
from the USA, the UK, and the Bill & Melinda Gates 
Foundation. The key disbursing agencies for these 
resources were USA bilateral organisations, non-
governmental organisations, and the World Bank 
(figure 2B).
Figure 3A shows the flow of development assistance for 
health contributions toward COVID-19 from the original 
source of funds, through the disbursing agency, and to the 
targeted programme area of focus as available for 2020. 
A total of $13·7 billion was disbursed in 2020 toward 
addressing the health-related effects of COVID-19 in 
low-income and middle-income countries. Of this total, 
the largest bilateral contributors were Japan ($2·3 billion), 
Germany ($1·3 billion), and the USA ($0·9 billion). 
Most of Japan’s support ($1·4 billion) was disbursed 
through its own bilateral agencies, mostly the Japanese 
Interna tional Cooperation Agency, and was targeted 
to India ($360·6 million), Morocco ($204·7 million), 
and Indonesia ($194·4 million). Sub-Saharan Africa 
($2·7 billion); south Asia ($2·2 billion); and southeast 
Asia, east Asia, and Oceania ($2·0 billion) were the main 
geographical super-regions that received COVID-19 funds. 
Both the UK and Germany primarily supported the 
Coalition for Epidemic Preparedness Innovations (CEPI; 
$64·3 million from the UK and $56·9 million from 
Germany). The Asian Development Bank, Gavi, and the 
Global Fund are the international development agencies 
that channelled most of the resources committed or 
disbursed for COVID-19.
Figure 3B shows the allocation of development 
assistance for health for COVID-19 in the GBD super-
regions. 23·5% of donors’ COVID-19 resources were for 
global initiatives and did not directly target a single 
country or region. Examples of such investments include 
vaccine development and procurement, and partner 
organisations’ coordination. The specific region to 
receive the most development assistance for health for 
COVID-19 was sub-Saharan Africa (28·8%). This figure 
also illustrates the poor alignment between COVID-19 
assistance for health and COVID-19 burden. In 2020, 
34·3% of recorded COVID-19 deaths in low-income and 
middle-income countries occurred in Latin America, but 
countries in Latin America received 7·7% of all 
development assistance for health for COVID-19 
allocated to any specific country.
The proportion of COVID-19 funds that were new 
resources versus those that were previously budgeted 
and repurposed to COVID-19 is shown in figure 4. Of 
the total $13·7 billion in development assistance for 
health for COVID-19, $1·4 billion (9·9%) was money 
from already existing projects that was redirected toward 
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COVID-19-related response activities. $12·3 billion 
(90·1%) of this funding was additional, previously 
unbudgeted resources. Across the disbursing entities, 
the Asian Development Bank ($1·8 billion) and Gavi 
($1·8 billion) disbursed most of their resources as new 
money. Relative contributions for health and non-health 
response are shown in table 2. The health response 
accounted for 9·8% of the overall response, with the 
non-health response making up the dominant share 
($125·4 billion) of the disbursed response. The types of 
contributions made and disbursed across the various 
disbursing agencies as part of the health-related 
COVID-19 response are shown in table 3. Grants made 
up most contributions, at $8·7 billion (63·6%), 
compared with loans at $4·8 billion (34·9%).
Relative to global spending, development assistance for 
health for COVID-19 remained small in 2020 (0·1%), and 
it is too early to know how much domestic spending has 
focused on COVID-19. Although there is a great deal of 
uncertainly, future spending on health is expected to 
continue to climb, albeit at a slower pace than anticipated 
before the pandemic. We estimated that global spending 
on health will reach $9·9 trillion (95% UI 9·7–10·1) 
in 2030 and $14·3 trillion (13·7–15·0) in 2050. Health 
spending over time for each income group is shown in 
figure 5, which highlights that health spending disparities 
are expected to persist and that there is a great deal of 
variation in total spending within income groups. We 
estimate that in 2050, low-income countries will spend 
$46 (95% UI 44–47) per person, lower-middle-income 
countries will spend $150 (141–159) per person, upper-
middle-income countries will spend $1001 (922–1083) 
per person, and high-income countries will spend $8536 
(8074–9032) per person.
Discussion
The context in which COVID-19 has spread globally is 
one of grave inequality in access to health services.39,40 
This research highlights how this inequality exists at the 
national level within the health sector. In 2019, national 
health spending ranged from $7 to $11 345 per person, 
with government health spending ranging from 
$2 to $6578 per person (table 1, appendix p 142). 
Development assistance for health reached $40·4 billion 
in 2019 and increased to $54·8 billion in 2020 because of 
the additional resources provided in response to 
COVID-19. Although development assistance for health 
makes up less than 1·0% of health spending in most 
middle-income countries, development assistance for 
health was 24·6% (95% UI 24·0–25·1) of total health 
spending in low-income countries. Health spending per 
person has grown almost universally between 1995 
and 2019 and is expected to rise in 195 of 204 countries 
and territories to 2050, but expected spending remains 
Figure 4: Type of health assistance provided towards the COVID-19 pandemic, 2020
This figure shows the amount of global development assistance for health for the COVID-19 pandemic that was repurposed versus new spending. Overall, 90·1% of 
global development assistance for health was new money, and 9·9% was repurposed money. ADB=Asian Development Bank. AfDB=African Development Bank. 
CEPI=Coalition for Epidemic Preparedness Innovations. GAVI=Gavi, the Vaccine Alliance. Global Fund=The Global Fund to Fight AIDS, Tuberculosis and Malaria. 
IDB=Inter-American Development Bank. NGO=Non-governmental organisation. PAHO=Pan American Health Organization. UNFPA=UN Population Fund.
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highly unequal. The finding of rising global health 
spending before the onset of the pandemic is aligned 
with what is reported in the WHO 2020 Global Health 
Spending Report.4 In both our study and WHO spending 
report, the pandemic is expected to perpetuate already 
existing vulnerabilities in global health spending, such as 
inequalities in spending across and within income 
groups.
Our estimates of development assistance for health for 
COVID-19 show that in 2020, a total of $13·7 billion was 
disbursed to aid the health response in low-income and 
middle-income countries. This figure constituted over a 
quarter of all development assistance for health, and is 
evidence of how resources can be scaled quickly when 
needed. Resources focused on country-level coordination, 
supply chain and logistics, case management and 
treatment, surveillance, rapid-response teams, case 
investigation, maintaining essential health services and 
systems, and infection prevention and control have 
received modest contributions.
Previous estimates of development assistance for 
health for COVID-19 vary greatly, primarily because each 
set of estimates focused on tracking different aspects of 
the international response. Our total estimates of 
resources committed is similar to that reported by the 
Economist Intelligence Unit COVID-19 Health Funding 
Tracker, which estimated $13·8 billion pledged as of 
December, 2020, although it excluded support for 
individual countries. Our estimates of resources 
committed are much smaller in magnitude, however, 
than what is reported by the other trackers. As of its last 
update in April 2020, the Kaiser Family Foundation 
estimated $19 billion had been pledged toward the health 
sector response.24 As of Jan 20, 2021, the Centre for 
Disaster Protection online visualisation tool reported 
$100·7 billion had been committed in loans (concessional 
and non-concessional) and $14·24 billion had been 
For more on the COVID-19 
health funding tracker see 
https://covidfunding.eiu.com
Total New funds Repurposed funds Commitment Disbursement Grant Loan
African Development Bank 566·3 566·3 ·· 589·1 566·3 137·7 428·5
Asian Development Bank 1817·0 1817·0 ·· 2103·1 1817·0 184·0 1633·0
Bilateral development agencies 2775·5 2493·4 282·0 3057·3 2775·5 1542·1 1032·7
Bill & Melinda Gates Foundation 313·3 313·3 ·· 313·3 313·3 313·3 ··
Coalition for Epidemic Preparedness 
Innovations
278·7 278·7 ·· 598·0 278·7 227·8 51·0
European Commission 605·6 565·9 39·6 718·9 605·6 605·6 ··
Gavi, the Vaccine Alliance 1903·3 1827·2 76·1 1903·3 ·· 1903·3 ··
The Global Fund 977·9 257·3 720·7 977·9 ·· 977·9 ··
Inter-American Development Bank 363·9 363·9 ·· ·· 363·9 ·· 363·9
Non-governmental organisation 280·6 267·5 13·1 153·1 280·6 280·6 ··
Pan American Health Organization 218·7 218·7 ·· ·· 218·7 218·7 ··
UNAIDS 9·0 0·6 8·4 27·3 9·0 9·0 ··
United Nations Population Fund 96·9 56·5 40·4 30·3 74·2 96·9 ··
UNICEF 614·2 506·3 107·9 140·0 485·9 614·2 ··
Unitaid 17·7 ·· 17·7 ·· 17·7 17·7 ··
USA foundations* 93·7 93·7 ·· 93·7 ·· 93·7 ··
World Bank International Bank for 
Reconstruction and Development
913·1 873·1 40·0 694·5 913·1 ·· 913·1
World Bank International Development 
Association
528·5 519 9·4 442·4 528·5 181·0 347·4
WHO 1295·5 1295·5 ·· 7508·4 1295·5 1295·5 ··
Total 13 669·4 12 313·9 1355·3 19 350·6 10 543·5 8699 4769·6
Spending data are reported in millions of 2020 US$, where estimates were available. In-kind contributions such as personal protective equipment was assumed to be grants. 
$200·7 million in bilateral development agencies funds were not able to be identified as either grants or loans. *Commitments of at least $10 000 from USA foundations 
internationally and in the USA.





Commitment 243·804 61·5121 182·2919
Disbursement 139·1044 13·66932 125·4351
Units are billion US$. Using IHME’s estimate of health-related disbursements, we 
estimated commitments and disbursements by health and non-health spending 
using data from the United Nations’ Office for the Coordination of Humanitarian 
Affairs Financial Tracking Service, compiled by the Center for Disaster Protection.38 
In the case where a grant was allocated to multiple sectors (health, as well as one 
or more non-health sectors), we calculated the funds attributed to health 
spending by multiplying the total grant amount by 1 divided by the number of 
sectors represented. Proportions of global commitments and disbursements by 
type of spending (health and non-health) were multiplied by IHME’s estimate of 
health-related disbursements. IHME=Institute for Health Metrics and Evaluation.
Table 2: Estimates of global COVID-19-related disbursements and 
commitments of health and non-health funds, 2020
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committed in grants.25 A key difference between these 
estimates and our own is that most of the other research 
on this topic has not estimated disbursements, and 
instead focused on commitments or pledges. In practice, 
disbursements are generally less than com mitments. 
Moreover, in the case of unexpected crisis, disbursing 
resources can take much longer than the time span that 
we have predicted. As of Dec 13, 2020, the Devex database 
reported 987 programme announcements worth 
$193·1 billion, 810 grants worth $2·9 billion, 2171 tenders 
worth $4·7 billion, and 1133 contracts worth $1·7 billion.26 
Unlike our estimates, these have a much broader focus 
and include support for the humanitarian response 
(outside of the health sector).
Only a few studies have estimated the resources needed 
for an effective pandemic response.3,12 Previously, the 
Commission on a Global Health Risk Framework for the 
Future, which was set up after the Ebola epidemic, 
estimated that annually $4·5 billion was needed globally 
for pandemic preparedness, by contrast with an expected 
annual loss of more than $60 billion from potential 
pandemics. One study12 on a sample of 73 low-income 
and middle-income countries estimated that the 
additional cost of responding to the COVID-19 pandemic 
was between $33 billion and $62 billion.
One consequence of the COVID-19 pandemic that is 
different from other recent epidemics, such as the Ebola 
outbreak in 2014 or MERS-CoV in 2012, is the significant 
economic toll on high-income countries. Precisely 
how the economic recession will affect governments’ 
willingness to maintain record development assistance 
resources for low-income and middle-income countries 
is not known. Some countries have already restructured 
their aid budgets to prioritise addressing domestic 
challenges. For instance, the UK has passed a bill to 
reduce the foreign aid commitment from 0·7% of GDP 
to 0·5% of GDP to enable management of the national 
budget.41 In addition to this, Kobayashi and colleagues42 
suggest that the global scale of the COVID-19 pandemic 
might have weakened public sentiment about con-
tributing public resources abroad, given the immense 
challenges at home. In the next decade, development 
assistance for health disbursements might grow at a 
substantially slower pace and could rely more heavily on 
private philanthropy and multilateral institutions.
Nonetheless, as the pandemic has evolved, so have calls 
for support for low-income and middle-income countries. 
These calls for support are not only to address immediate 
health needs but also to provide additional social safety 
net support and economic relief. Multilateral institu-
tions such as the IMF, the World Bank, and regional 
development banks including the Asian Development 
Bank, the Inter-American Development Bank, and the 
African Development Bank have all responded promptly 
to these requests with various packages. However, much 
of this support consists of loans that will add to national 
debt, with potential for long-term effects on growth and 
the ability to increase social spending.43 Additionally, 
there are calls for debt repayment suspension and 
a repurposing of such resources towards bolstering 
struggling economies.
The pandemic’s effect on other essential service 
provisions has been notable, largely because addressing 
the urgent demands of the pandemic required a 
realignment of health resources, including personnel, 
hospital supplies, services, data, and funding, and has 
made accessing health services safely substantially more 
challenging.44 At the beginning of the pandemic, when 
some health-care systems were overwhelmed by the 
unfolding crisis, the complete refocus of resources 
seemed to be the most logical response. However, over 
time, this burden on the health system has made evident 
the importance of strong health systems worldwide in 
maintaining global health security, and made it even 
more obvious that targeting development assistance 
Figure 5: Distribution of total health spending per capita in 2019 and 2050 by income group
(A) 2019. (B) 2050. Estimates are reported in 2020 US$. The x-axes are presented in a natural logarithmic scale. 
Vertical lines represent the mean for each distribution. The World Bank income classification does not include Cook 
Islands, Niue, and Tokelau. The Cook Islands and Niue were assigned to the high-income group, and Tokelau was assigned 
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contributions to the strengthening of the broader health 
system is a crucial investment for global health security 
overall.45,46 Although contributions toward health system 
strengthening have improved, the relative proportion of 
development assistance funds that are targeted toward 
such activities remains small, with an even smaller 
amount allocated toward pandemic preparedness.47 The 
pandemic has shown how quickly a local epidemic can 
develop into a global crisis, and the need for global 
activity and cooperation to be commensurate with this 
challenge.
The COVID-19 pandemic has also had ramifications 
for the Sustainable Development Goals (SDGs) more 
broadly. According to the SDGs Report 2020,48,49 globally, 
progress has been insufficient and the pandemic has 
only worsened the precarious progress made on most 
of the goals. For instance, in several countries in sub-
Saharan Africa it seemed the health toll of the pandemic 
was less than expected in 2020, but the economic fallout 
due to public health measures such as lockdowns might 
have had much more severe consequences and pushed 
an additional 23 million people into poverty.50,51 The 
mitigation strategies used to reduce the impact of 
the pandemic have also led to a meaningful global 
response. So far, development assistance contribution 
that falls outside of the health sector has been much 
larger than health-related contributions ($125·4 billion 
vs $13·7 billion). This reflects how the effect of the 
COVID-19 pandemic has reverberated outside of the 
health sector, affecting the social, economic, and 
environ mental sectors in most countries.
Another challenge associated with raising and 
disbursing record-setting amounts of development 
assistance is the crucial task of allocating these scarce 
resources. Despite the differences in the burden of the 
pandemic across geographical regions, the patterns in 
the allocation of development assistance for health for 
COVID-19 remain largely the same as development 
assistance for health in the past, with Latin America and 
the Caribbean receiving little support despite their high 
burden. In future, key contributions must be aligned 
with where they are needed the most.
The distribution of the COVID-19 vaccine has 
generated much public discourse.52 Although the initial 
discussion in popular media and among policy makers 
focused on national interests, the Access to COVID-19 
Tools (ACT) Accelerator partnership was launched in 
April, 2020, by WHO, the European Commission, and 
the French Government to ensure pooled and equitable 
distribution of tools to fight COVID-19. ACT-Accelerator 
was estimated to need $33 billion for its work. 
Of ACT-Accelerator’s four key pillars, the pillar that 
focuses on vaccines is the COVID-19 Vaccines Global 
Access Facility, which is led by Gavi, WHO, and CEPI. 
Leveraging its previous experience with managing 
advanced market commitment for immunisation, Gavi 
was tasked with facilitating the procurement of vaccines 
for 92 middle-income countries through the COVID 
advance market commitment. The objective was to raise 
$2 billion before the end of 2020 to enable it to sup-
port access to vaccines irrespective of income.53 As of 
August, 2021, $17·9 billion had been committed to the 
ACT Accelerator partnership.
COVID-19 has highlighted the nuanced role health 
systems play in providing health security. Although 
robust health systems—with capacity to test, track, and 
treat those with the virus and ability to access and provide 
vaccines quickly and efficiently—are necessary for 
keeping deaths from COVID-19 at bay, it has also been 
made clear that a robust health system alone is not 
sufficient.54 COVID-19 mortality rates have varied greatly 
across the globe, but there is little consensus on what is 
driving this variation, with key historical measures of 
pandemic preparedness highlighting capacity gaps, but 
not accurately predicting where the outcomes will be the 
best or worst.55 To be successful in fighting the virus 
and preventing substantial loss, a constellation of 
characteristics that fall both inside and outside of the 
traditional health system is necessary. These char-
acteristics include leadership, public health system 
capacity, social safety nets, and trust in the systems 
providing information and care.56,57 A painful lesson of 
this pandemic is that global health security is only as 
strong as its weakest link. It is crucial that those working 
in the health sector ensure that the entire health system 
is in fact robust, and that policy makers outside of the 
health sector also be prepared for many potential crises 
that can accompany a pandemic.
This research highlights the context in which 
COVID-19 spread quickly across the globe—one of 
enormous variation in health-care spending. Robust 
health systems require more resources, and those 
working in government and advocacy outside of the 
health sector are encouraged to see COVID-19 and the 
staggering loss of life and broader setbacks in global 
development as indicators of the importance of investing 
in health in and outside the health system, and building 
governments and social systems that can also contribute 
towards health security.
This study has several limitations. The data were 
extracted from multiple sources with different reporting 
structures and components included. We kept definitions 
and methods as consistent as possible across data sources 
to ensure a reliable estimate of resources. Furthermore, 
given that the pandemic is ongoing and development 
projects take some time to reach implementation, 
disbursement could still be low even where commitments 
have been made. Moreover, global health resource 
tracking does not allow comparable tracking of how 
domestic resources are spent on health and does not 
allow for comprehensive estimates of domestic health 
spending on COVID-19. More information is needed to 
assess how governments, households, and private 
organisations are spending health resources, and what 
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resources are available for responding to health emer-
gencies. Health financing reporting, especially in many 
low-income and middle-income countries, but also in 
high-income countries, is constrained by how timely 
domestic health spending data are available. Health 
financing data are not collated in a manner that is 
shareable or comparable across time and country. As 
countries deliberate on ways to rebuild systems after 
the pandemic, the health financing architecture and 
equity are important aspects to consider. Finally, our 
quantification of uncertainty captures some types of 
uncertainty, but not all types of uncertainty. It is included 
here as a relative quantification of where we have the 
most confidence in our estimates.
Health spending in 2019, before the COVID-19 pan-
demic, ranged widely, and marks tremendous variation 
in the access to essential health services and universal 
health coverage. Much more money is needed to fully 
address the effects of the pandemic in most low-income 
and middle-income countries, along with access to key 
tools such as vaccines. Moreover, long-term projections 
suggest that health inequalities are likely to persist and 
that international efforts to invest in global public goods 
related to global pandemic preparedness are essential. 
Resources are needed urgently to mitigate the loss 
associated with the COVID-19 pandemic and fund 
systems that can prevent and respond quicker to the next 
global health crisis.
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